NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKI

被引：6

作者：

Facchinetti, Francesco ^{[1
]}

Tiseo, Marcello ^{[1
]}

Gnetti, Letizia ^{[2
]}

Silini, Enrico Maria ^{[2
]}

Ardizzoni, Andrea ^{[1
]}

机构：

[1] Univ Hosp Parma, Med Oncol Unit, I-43100 Parma, Italy

[2] Univ Hosp Parma, Surg Pathol Unit, I-43100 Parma, Italy

来源：

LUNG CANCER | 2013年 / 82卷 / 01期

关键词：

CARCINOMA;

D O I：

10.1016/j.lungcan.2013.07.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：177 / 178

页数：2

共 50 条

[21] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
da Silva, L. L.
Matsas, S.
Aguiar, P., Jr.
Taveira, G. M. T.
Barcelos, I. F.
Lopes, G. L., Jr.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
[22] Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Yamaoka, Toshimitsu
Ohmori, Tohru
Ohba, Motoi
Arata, Satoru
Kishino, Yasunari
Murata, Yasunori
Kusumoto, Sojiro
Ishida, Hiroo
Shirai, Takao
Hirose, Takashi
Ohnishi, Tsukasa
Sasaki, Yasutsuna
MOLECULAR CANCER THERAPEUTICS, 2016, 15 (12) : 3040 - 3054
[23] SLK Causes Resistance to EGFR-TKI in Lung Cancer
Ashraf, K.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2371 - S2372
[24] Evaluation of EGFR degradation as a mechanism of tumor evasion in EGFR-TKI resistant non-small cell lung cancer (NSCLC) cells compared to EGFR-TKI sensitive cells
Norma, Hernandez-Pedro Y.
Giovanny, Soca-Chafre
Mario, Orozco-Morales
Pedro, Barrios-Bernal
Oscar, Arrieta
CANCER RESEARCH, 2018, 78 (13)
[25] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
Dong, Kai
Liang, Wenhua
Zhao, Shen
Guo, Minzhang
He, Qihua
Li, Caichen
Song, Haiqing
He, Jianxing
Xia, Xiaojun
TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 268 - +
[26] The IASLC Grading System as a Predictor For EGFR-TKI Therapy in EGFR-Mutant Lung Adenocarcinoma
Deng, C.
Chen, H.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S175 - S175
[27] Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells
Kinehara, Yuhei
Nagatomo, Izumi
Koyama, Shohei
Ito, Daisuke
Nojima, Satoshi
Kurebayashi, Ryota
Nakanishi, Yoshimitsu
Suga, Yasuhiko
Nishijima-Futami, Yu
Osa, Akio
Nakatani, Takeshi
Kato, Yasuhiro
Nishide, Masayuki
Hayama, Yoshitomo
Higashiguchi, Masayoshi
Morimura, Osamu
Miyake, Kotaro
Kang, Sujin
Minami, Toshiyuki
Hirata, Haruhiko
Iwahori, Kota
Takimoto, Takayuki
Takamatsu, Hyota
Takeda, Yoshito
Hosen, Naoki
Hoshino, Shigenori
Shintani, Yasushi
Okumura, Meinoshin
Kumagai, Toru
Nishino, Kazumi
Imamura, Fumio
Nakatsuka, Shin-ichi
Kijima, Takashi
Kida, Hiroshi
Kumanogoh, Atsushi
JCI INSIGHT, 2018, 3 (24):
[28] Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
Takeda, Masayuki
Okamoto, Isamu
Tsurutani, Junji
Oiso, Naoki
Kawada, Akira
Nakagawa, Kazuhiko
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (06) : 528 - 533
[29] EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study
Gieszer, Balazs
Megyesfalvi, Zsolt
Dulai, Viktoria
Papay, Judit
Kovalszky, Ilona
Timar, Jozsef
Fillinger, Janos
Harko, Tunde
Pipek, Orsolya
Teglasi, Vanda
Regos, Eszter
Papp, Gergo
Szallasi, Zoltan
Laszlo, Viktoria
Renyi-Vamos, Ferenc
Galffy, Gabriella
Bodor, Csaba
Dome, Balazs
Moldvay, Judit
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (02) : 662 - +
[30] Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance
Lee, Jeong Eun
Park, Hee Sun
Lee, Dahye
Yoo, Geon
Kim, Tackhoon
Jeon, Haeyon
Yeo, Min-Kyung
Lee, Choong-Sik
Moon, Jae Young
Jung, Sung Soo
Kim, Ju Ock
Kim, Sun Young
Park, Dong Il
Park, Yeon Hee
Lee, Jae Cheol
Oh, In-Jae
Lim, Dae Sik
Chung, Chaeuk
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 474 (01) : 154 - 160

← 1 2 3 4 5 →